1. Home
  2. GNPX vs PPBT Comparison

GNPX vs PPBT Comparison

Compare GNPX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$1.68

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

N/A

Current Price

$1.59

Market Cap

2.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
PPBT
Founded
2009
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.4M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
GNPX
PPBT
Price
$1.68
$1.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 110.6K
26.5K
Earning Date
11-13-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.41
52 Week High
$9.99
$5.18

Technical Indicators

Market Signals
Indicator
GNPX
PPBT
Relative Strength Index (RSI) 31.86 63.53
Support Level $0.80 $1.39
Resistance Level $2.42 $1.85
Average True Range (ATR) 0.19 0.16
MACD -0.01 0.05
Stochastic Oscillator 2.80 78.20

Price Performance

Historical Comparison
GNPX
PPBT

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.

Share on Social Networks: